FMS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Fresenius Medical Care AG & Co. KGaA

CEO
Rice Powell
Employees
125364
Headquarters

Else-Kroener-Strasse 1
Bad Homburg Vor Der Hohe, Hessen 61352
Phone: 4961726090
https://www.freseniusmedicalcare.com/

News

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Apr 24, 2024 07:00am

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland , Liechtenstein and Norway . "This is a significant step forward for patients in Europe living with IgAN, a rare and serious condition, and a leading cause of end stage renal disease," said Prof. Dr. med. Jürgen Floege, Senior Professor, Div. Nephrology and Clinical Immunology at the University Hospital, RWTH Aachen, Germany , and steering committee member for the PROTECT clinical trial. "The approval of this innovative treatment is based on data from the only head-to-head phase-III clinical trial in IgAN.


Source:PR Newswire Asia (English)
Opioid Kappa Receptor Agonists Market to Witness Significant Growth by 2034, Asserts DelveInsight | Fresenius Medical Care, Cara Therapeutics, Toray Industries, Torii Pharma
Apr 04, 2024 12:35pm

The Opioid Kappa Receptor Agonists market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is likely to


Source:OpenPR
What Makes Fresenius Medical Care AG (FMS) a Potential Investment?
Mar 25, 2024 14:59pm

Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global fund returned +8.40% gross of fees (+8.18% net of fees), compared to the MSCI ACWI Index’s +11.03%, and the MSCI ACWI Value Index’s +9.17% gains. […]


Source:Insider Monkey
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care | FMS Stock News
Mar 22, 2024 12:00pm

Fresenius Medical Care (FME) delivers on commitments during a year of fundamental transformation, making progress towards sustainability goals in key areas such as patient satisfaction, diversity in management, and climate target roadmap.


Source:Stock Titan
EQS-DD: Fresenius Medical Care AG: Franklin W. Maddux, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2021)
Mar 19, 2024 13:06pm

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2024 / 14:05 CET/CEST The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
EQS-DD: Fresenius Medical Care AG: Dr. Katarzyna Mazur-Hofsäß, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2021)
Mar 19, 2024 13:03pm

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2024 / 14:02 CET/CEST The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
EQS-DD: Fresenius Medical Care AG: Helen Pring Giza, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2021)
Mar 19, 2024 13:01pm

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
Mar 19, 2024 12:00pm

For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous…


Source:PR Newswire
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Mar 05, 2024 20:21pm

Tuesday, Novo Nordisk A/S (NYSE: NVO ) released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people treated with semaglutide 1.0 mg compared to placebo . Stocks of kidney dialysis-focused DaVita Inc (NYSE: DVA ), Fresenius Medical Care AG (NYSE: FMS ), and Baxter International Inc (NYSE: BAX ) shares fell sharply when Novo Nordisk stopped the … Full story available on Benzinga.com


Source:Benzinga